502257_sm1.doc (559 kB)
Download file

Supplementary Material for: Metformin and Aging: A Review

Download (559 kB)
dataset
posted on 13.09.2019, 08:59 by Glossmann H.H., Lutz O.M.D.
Metformin is sometimes proposed to be an “anti-aging” drug, based on preclinical experiments with lower-order organisms and numerous retrospective data on beneficial health outcomes for type 2 diabetics. Large prospective, placebo-controlled trials are planned, in pilot stage or running, to find a new use (or indication) for an aging population. As one of the metformin trials has “frailty” as its endpoint, similar to a trial with a plant-derived senolytic, the latter class of novel anti-aging drugs is briefly discussed. Concerns exist not only for vitamin B12 and B6 deficiencies, but also about whether there are adverse effects of metformin on individuals who try to remain healthy by maintaining cardiovascular fitness via exercise.

History

Usage metrics

Read the peer-reviewed publication

Categories

Licence

Exports